Skip to main content

Advertisement

SpringerLink
Log in

Development of a More Efficient Albumin-Based Delivery System for Gambogic Acid with Low Toxicity for Lung Cancer Therapy

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Gambogic acid (GA) has been proven to be a potent chemotherapeutic agent for the treatment of lung cancer in clinical trials. However, GA is limited in its therapeutic value by properties such as poor water solubility and low chemical stability. In clinical trials, cationic arginine (Arg) was added to solubilize GA, and this may also cause other side effects. Here, we have designed and developed a more efficient human serum albumin (HSA)-based delivery system for GA with low toxicity which helps improve its solubility, chemical stability and increases its antitumor efficacy. The GA-HSA nanoparticles (NPs) were prepared by albumin-bound (nabTM) technology, with a particle size of 135.2 ± 35.03 nm, a zeta potential of −21.81 ± 1.24 mV, and a high entrapment efficiency. Compared with GA-Arg solution, the physical and chemical stability of the NPs were improved when stored at pH 7.4 in PBS or freeze-dried. The in vitro drug release showed that GA-HSA NPs had a more sustained release than GA-Arg solution. Furthermore, HSA NPs improved the therapeutic efficacy of GA and were less toxic compared with GA-Arg solution in A549-bearing mice. Therefore, this delivery system is a promising polymeric carrier for GA when used for tumor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Sesen MB, Kadir T, Alcantara RB, et al. Survival prediction and treatment recommendation with Bayesian techniques in lung cancer. AMIA Symposium. 2012;838–47.

  2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.

    Article  PubMed  Google Scholar 

  3. Zhu X, Zhang H, Lin Y, et al. Mechanisms of gambogic acid-induced apoptosis in non-small cell lung cancer cells in relation to transferring receptors. J Chemother. 2009;21(6):666–72.

    Article  CAS  PubMed  Google Scholar 

  4. Yang Y, Yang L, You QD, et al. Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett. 2007;256(2):259–66.

    Article  CAS  PubMed  Google Scholar 

  5. Pandey MK, Sung B, Ahn KS, et al. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood. 2007;110(10):3517–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhao L, Guo QL, You QD, et al. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull. 2004;27(7):998–1003.

    Article  CAS  PubMed  Google Scholar 

  7. Chen J, Gu HY, Lu N, et al. Microtubule depolymerization and phosphorylation of c-Jun N-terminal kinase-1 and p38 were involved in gambogic acid induced cell cycle arrest and apoptosis in human breast carcinoma MCF-7 cells. Life Sci. 2008;83(3–4):99–110.

    Google Scholar 

  8. Guo Q, Qi Q, You Q, et al. Toxicological studies of gambogic acid and its potential targets in experimental animals. Basic Clin Pharmacol Toxicol. 2006;99(2):178–84.

    Article  CAS  PubMed  Google Scholar 

  9. Qi Q, You Q, Gu H, et al. Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol. 2008;117(3):433–8.

    Article  CAS  PubMed  Google Scholar 

  10. Hao K, Liu XQ, Wang GJ, et al. Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats. Eur J Drug Metab Pharmacokinet. 2007;32(2):63–8.

    Article  CAS  PubMed  Google Scholar 

  11. Han QB, Cheung S, Tai J, et al. Stability and cytotoxicity of gambogic acid and its derivative, gambogoic acid. Biol Pharm Bull. 2005;28(12):2335–7.

    Article  CAS  PubMed  Google Scholar 

  12. Lundberg BB, Risovic V, Ramaswamy M, et al. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release. 2003;86(1):93–100.

    Article  CAS  PubMed  Google Scholar 

  13. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60.

    Article  CAS  PubMed  Google Scholar 

  14. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev. 2009;61(10):768–84.

    Article  CAS  PubMed  Google Scholar 

  15. Egusquiaguirre SP, Igartua M, Hernández RM, et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012;14(2):83–93.

    Article  CAS  PubMed  Google Scholar 

  16. Wiradharma N, Zhang Y, Venkataraman S, et al. Self-assembled polymer nanostructures for delivery of anticancer therapeutics. Nano Today. 2009;4(4):302–17.

    Article  CAS  Google Scholar 

  17. Galisteo-González F, Molina-Bolívar JA. Systematic study on the preparation of BSA nanoparticles. Colloids Surf B: Biointerfaces. 2014;123(139):286–92.

    Article  PubMed  Google Scholar 

  18. Fu Q, Sun J, Zhang W, et al. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat Anticancer Drug Discov. 2009;4(3):262–72.

    Article  CAS  PubMed  Google Scholar 

  19. Gao S, Sun J, Fu D, et al. Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. Int J Pharm. 2012;427(2):410–6.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang ZH, Wang XP, Aym WY, et al. Studies on lactoferrin nanoparticles of gambogic acid for oral delivery. Drug Deliv. 2013;20(1):86–93.

    Article  CAS  PubMed  Google Scholar 

  21. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;157(2):168–82.

    Article  CAS  PubMed  Google Scholar 

  22. Zhao D, Zhao X, Zu Y, et al. Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles. Int J Nanomedicine. 2010;5(4):669–77.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Zu Y, Yu Z, Zhao X, et al. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate-conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Inter J Nanomedicine. 2008;4(1):321–33.

    Google Scholar 

  24. Rothweiler F, Michaelis M, et al. Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm. 2007;341(1–2):207–14.

    PubMed  Google Scholar 

  25. Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011;63(6):456–69.

    Article  CAS  PubMed  Google Scholar 

  26. Ge F, Chen C, Liu D, et al. Study on the interaction between theasinesin and human serum albumin by fluorescence spectroscopy. J Lumin. 2010;130(1):168–73.

    Article  CAS  Google Scholar 

  27. Li C, Zhang D, Guo H, et al. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Int J Pharm. 2013;448(1):79–86.

    Article  CAS  PubMed  Google Scholar 

  28. Liu F, Li M, Liu C, et al. PH-sensitive self-assembled carboxymethyl chitosan-modified DNA/polyethylenimine complexes for efficient gene delivery. J Biomed Nanotechnol. 2014;10(11):3397–406.

    Article  CAS  PubMed  Google Scholar 

  29. Anhorn MG, Mahler HC, Langer K. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients. Int J Pharm. 2008;363(1–2):162–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Normal College, Shenyang University, No.54, Lianhe Road, Shenyang, 110044, China

    Yan Zhang & Zaixing Yang

  2. Kelun Pharmaceutical Co., Ltd, Tianjin, 300450, China

    Zhijie Yang

  3. Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China

    Xinyi Tan & Xing Tang

Authors
  1. Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhijie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinyi Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xing Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zaixing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zaixing Yang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Yang, Z., Tan, X. et al. Development of a More Efficient Albumin-Based Delivery System for Gambogic Acid with Low Toxicity for Lung Cancer Therapy. AAPS PharmSciTech 18, 1987–1997 (2017). https://doi.org/10.1208/s12249-016-0670-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-016-0670-4

KEY WORDS

Search

Navigation